Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

Inclusion Criteria: * Diagnosis of type 2 diabetes ≥ 3 months. * Stable regimen of diet and exercise in combination with a stable treatment of liraglutide ≥1.2 mg/day and metformin ≥1000 mg/day. * HbA1c ≤9.5%. * Stable body weight ≥ 3 months. * Body mass index (BMI) ≥25 to ≤45 kg per meter squared. * Calcitonin \<50 ng/L (50 pg/mL) at the Screening Visit. Exclusion Criteria: * History of type 1 diabetes. * Recent use or of anti-diabetic medications other than liraglutide or metformin. * History of significant/severe nausea and/or vomiting due to liraglutide. * Significant symptomatic hyperglycemia. * History or evidence, within the last 6 months prior to the Screening Visit, of myocardial infarction, coronary revascularization (coronary artery bypass grafting or percutaneous coronary intervention), unstable angina, or cerebrovascular accident or stroke. * History or evidence of acute or chronic pancreatitis. * History of liver disease. * History of medullary thyroid cancer or a family or personal history of multiple endocrine neoplasia type 2. * Poor thyroid, liver, or renal function. * Serum creatinine levels \>1.5mg/dL (132 μmol/L) for male patients, or \>1.4 mg/dL (123 μmol/L) for female patients. * Weight loss surgery or requires weight loss medications. * History of malignancy (not including basal or squamous cell carcinoma of the skin with past 5 years). * History of active alcohol or substance abuse. * Treatment with medications that affect GI motility. * History of hypersensitivity to exenatide or liraglutide. * Women that are pregnant, lactating, or planning to become pregnant.

Reproduced word-for-word from the public registry record — the study team can answer questions about it.